Lilly cuts wholesale price on some insulin, but impact is likely to be limited

Eli Lilly (LLY) announced plans to lower the wholesale price of certain insulin products by an additional 40% in January 2022, the latest bid by a drug maker to combat criticism that the cost of these life-saving diabetes treatments are out of reach for too many patients.

The move involves dropping the price of Insulin Lispro Injection in the U.S. to $82.41 for individual vials and $159.12 for a pack of five pens, which the company maintained will be 70% of the cost of Humalog U-100, a brand-name version of the product. The new wholesale price, which will lower the wholesale price for the product, will apply to all so-called authorized generic versions of Humalog that Lilly sells.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button